Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Mukund Paravasthu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,138
+47.29%
|
-
|
|
Nov 02
2024
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
44
-1.26%
|
$704
$16.69 P/Share
|
|
Nov 01
2024
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
160
-4.37%
|
$2,400
$15.88 P/Share
|
|
Nov 01
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
598
-0.37%
|
$8,970
$15.94 P/Share
|
|
Oct 31
2024
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
810
-0.73%
|
$12,150
$15.79 P/Share
|
|
Aug 02
2024
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
688
-0.31%
|
$13,760
$20.14 P/Share
|
|
Jun 28
2024
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,239
+7.52%
|
$14,868
$12.24 P/Share
|
|
Jun 28
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,055
+0.42%
|
$12,660
$12.24 P/Share
|
|
Jun 28
2024
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
930
+0.78%
|
$11,160
$12.24 P/Share
|
|
Jun 28
2024
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,736
+1.54%
|
$20,832
$12.24 P/Share
|
|
Jun 28
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
1,736
+1.06%
|
$20,832
$12.24 P/Share
|
|
Jun 28
2024
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,286
+0.58%
|
$15,432
$12.24 P/Share
|
|
Jun 05
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
124,373
+50.0%
|
$2,736,206
$22.82 P/Share
|
|
Jun 05
2024
|
Allyson J Ocean |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+50.0%
|
-
|
|
Jun 05
2024
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+17.08%
|
-
|
|
Jun 05
2024
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+23.5%
|
-
|
|
Jun 05
2024
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+4.65%
|
-
|
|
Jun 05
2024
|
Timothy J Scannell |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+33.68%
|
-
|
|
Jun 05
2024
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+2.33%
|
-
|
|
Jun 05
2024
|
Kristin Stafford |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+50.0%
|
-
|
|
Jun 05
2024
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+38.08%
|
-
|
|
Jun 04
2024
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
964
-1.22%
|
$22,172
$23.89 P/Share
|
|
Jun 04
2024
|
Timothy J Scannell |
SELL
Open market or private sale
|
Direct |
964
-24.54%
|
$22,172
$23.89 P/Share
|
|
Jun 04
2024
|
W Anthony Vernon |
SELL
Open market or private sale
|
Direct |
964
-0.58%
|
$22,172
$23.89 P/Share
|
|
Mar 04
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,217
-0.48%
|
$19,472
$16.01 P/Share
|
|
Mar 04
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
840
-0.52%
|
$13,440
$16.01 P/Share
|
|
Mar 01
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,107
-0.83%
|
$33,712
$16.03 P/Share
|
|
Mar 01
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,679
-1.03%
|
$26,864
$16.03 P/Share
|
|
Feb 28
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,078
-1.26%
|
$33,248
$16.14 P/Share
|
|
Feb 28
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,303
-0.9%
|
$36,848
$16.14 P/Share
|
|
Feb 27
2024
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
102,249
+31.74%
|
$1,635,984
$16.3 P/Share
|
|
Feb 27
2024
|
Nicolas Leupin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,124
+50.0%
|
$817,984
$16.3 P/Share
|
|
Feb 27
2024
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,574
+39.6%
|
$1,145,184
$16.3 P/Share
|
|
Feb 27
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
102,249
+38.3%
|
$1,635,984
$16.3 P/Share
|
|
Feb 27
2024
|
Moshe Giladi Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,124
+42.29%
|
$817,984
$16.3 P/Share
|
|
Feb 27
2024
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,799
+32.34%
|
$1,308,784
$16.3 P/Share
|
|
Feb 27
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,034
+15.48%
|
$752,544
$16.3 P/Share
|
|
Feb 27
2024
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
81,799
+41.12%
|
$1,308,784
$16.3 P/Share
|
|
Dec 31
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3
+0.0%
|
$36
$12.69 P/Share
|
|
Dec 31
2023
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
128
+0.36%
|
$1,536
$12.69 P/Share
|
|
Nov 07
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
382
-0.31%
|
$4,584
$12.65 P/Share
|
|
Nov 02
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
175
+0.15%
|
$1,925
$11.46 P/Share
|
|
Oct 31
2023
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,593
+50.0%
|
-
|
|
Oct 31
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,793
+5.0%
|
$177,930
$10.02 P/Share
|
|
Sep 01
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
273
-0.22%
|
$5,733
$21.82 P/Share
|
|
Sep 01
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
294
-0.14%
|
$6,174
$21.82 P/Share
|
|
Sep 01
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
883
-0.88%
|
$18,543
$21.82 P/Share
|
|
Aug 02
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,144
-1.13%
|
$34,320
$30.25 P/Share
|
|
Jun 30
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
366
+0.17%
|
$12,810
$35.28 P/Share
|
|
Jun 30
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
305
+0.34%
|
$10,675
$35.28 P/Share
|